HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 1122-1130

  Penuel, Elicia ^a   Li, Congfen ^a   Parab, Vaishali ^a   Burton, Luciana ^a   Cowan, Kyra J ^a   Merchant, Mark ^a   Yauch, Robert L ^a   Patel, Premal ^a   Peterson, Amy ^a   Hampton, Garret M ^a   Lackner, Mark R ^a   Hegde, Priti S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; ONARTUZUMAB; PLACEBO; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REPRODUCIBILITY; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84879298407     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0015     Document Type: Article

References (37)

1. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15:49-51.
2. Lokker NA, Mark MR, Luis EA, Bennett GL, Robbins KA, Baker JB, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992;11:2503-10.
3. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
4. Zhu H, Naujokas MA, Fixman ED, Torossian K, Park M. Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis. J Biol Chem 1994;269:29943-8.
5. Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, et al. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol 2011;30:341-54.
6. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
7. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005;11: 2222-8.
8. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9: 1480-8.
9. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011;3:171-84.
10. Moss RA BJ, Patel P, Peterson AC, Eppler S, Yu W, Ratain MJ, et al. Complete results from phase I dose escalation study of MetMAb, a monovalent antagonist antibody to the receptor met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies. ESMO 2010. Abstract 4378.
11. Spigel DR ET, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29, Abstract 7505.
12. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6:75-84.
13. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwal R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
14. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8.
15. Brunetto AT, Kristeleit RS, de Bono JS. Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncol 2010;6:1339-52.
16. Sarker D, Pacey S, Workman P. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomark Med 2007;1:399-417.
17. Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 2012;18:1798-807.
18. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 2009;125:1657-62.
19. Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, et al. Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Med Oncol 2012;29:1614-21.
20. Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer 2011;74: 293-9.
21. Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 2012;103:1189-94.
22. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
23. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
24. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-9.
25. Sakon M, Kita Y, Takeda Y, Higaki N, Ohzato H, Umeshita K, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 1999;29:110-3.
26. Li C, NI ZJ, Lipkind M, Patel P, Peterson A, et al. Circulating biomarkers of MetMAb activity in a phase 1a dose-escalating clinical trial. AACR 2010. Abstract 1670.
27. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207-14.
28. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16:699-710.
29. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011;17:7754-64.
30. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-9.
31. Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988;81:414-9.
32. Zarnegar R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res 1989;49:3314-20.
33. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999;19:151-9.
34. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995;1:1031-4.
35. Hosoda H, Izumi H, Tukada Y, Takagiwa J, Chiaki T, Yano M, et al. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. Ann Thorac Cardiovasc Surg 2012;18:1-7.
36. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 1991;88: 7001-5.
37. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69.